Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.

CONCLUSIONS: In conclusion, octreotide LAR is commonly prescribed in doses or schedules above the recommended dose and frequency. Patients with refractory carcinoid syndrome appear to experience a clinical benefit from this change. Prospective data may be used to further evaluate this strategy. PMID: 23936548 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/23936548?dopt=Abstract

Source: Gastrointestinal Cancer Research - June 4, 2015 Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research

More News: Cancer | Cancer & Oncology | Carcinoid Tumor | Gastroenterology | Radiography